Affiliation:
1. Saint Petersburg State Pediatric Medical University of the Ministry of Healthcare of the Russian Federation
2. Saint Petersburg State Pediatric Medical University of the Ministry of Healthcare of the Russian Federation; N.N. Petrov National Medical Research Center of Oncology of the Ministry of Healthcare of the Russian Federation
Abstract
Anthracycline chemotherapy drugs are widely used for the treatment of various tumors but they are associated with high cardiotoxicity. The novel coronavirus disease can also negatively affect the heart function. In this article, we report a case of anthracycline-related cardiotoxicity in a child with refractory acute lymphoblastic leukemia and the novel coronavirus disease, describing changes in instrumental and laboratory parameters observed over time during the treatment and providing a description of autopsy samples of the myocardium. The patient’s parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.
Publisher
Fund Doctors, Innovations, Science for Children
Subject
Oncology,Hematology,Immunology,Immunology and Allergy,Pediatrics, Perinatology and Child Health
Reference23 articles.
1. Asnani A., Neilan T.G., Tripathy D., Scherrer-Crosbie M. Clinical manifestations, monitoring, and diagnosis of anthracycline-induced cardiotoxicity. 2019. [Elektronnyi resurs] URL: https://www.uptodate.com/contents/clinical-manifestations-monitoring-and-diagnosis-of-anthracycline-induced-cardiotoxicity. (Accessed: 07.11.2022).
2. Cardinale D., Colombo A., Bacchiani G., Tedeschi I., Meroni S.A., Veglia F., et al (). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131 (22): 1981–8. DOI: 10.1161/CIRCULATIONAHA.114.013777
3. Obrezan A.G., Shcherbakova N.V. Lechenie onkologicheskikh zabolevanii i kardiotoksichnost': mekhanizmy vozniknoveniya i sovremennye podkhody k diagnostike serdechnoi nedostatochnosti u onkologicheskikh patsientov. Voprosy onkologii 2019; 65 (2): 172–80.
4. Sawaya H., Sebag I.A., Plana J.C., Januzzi J.L., Ky B., Tan T.C., et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5 (5): 596–603. DOI: 10.1161/CIRCIMAGING.112.973321
5. Cardinale D., Sandri M.T., Colombo A., Colombo N., Boeri M., Lamantia G., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109 (22): 2749–54. DOI: 10.1161/01.CIR.0000130926.51766.CC